Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTU NASDAQ:FNCH NASDAQ:NEUP OTCMKTS:ULUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.33+2.6%$2.35$0.95▼$2.85$20.38M0.2271,943 shs197,523 shsFNCHFinch Therapeutics Group$12.67-0.2%$12.63$10.15▼$15.85$20.35M1.22,176 shs2,533 shsNEUPNeuphoria Therapeutics$15.10+16.2%$8.58$2.12▼$15.14$24.42M0.5766,275 shs84,467 shsULURULURU$0.00$0.10▼$0.79$5.35M-3.136,691 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma+2.64%-0.85%-1.69%+20.73%-4.12%FNCHFinch Therapeutics Group-0.24%-2.54%+1.81%-7.52%+1.04%NEUPNeuphoria Therapeutics+16.24%+26.36%+103.23%+111.19%+1,509,999,900.00%ULURULURU0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.33+2.6%$2.35$0.95▼$2.85$20.38M0.2271,943 shs197,523 shsFNCHFinch Therapeutics Group$12.67-0.2%$12.63$10.15▼$15.85$20.35M1.22,176 shs2,533 shsNEUPNeuphoria Therapeutics$15.10+16.2%$8.58$2.12▼$15.14$24.42M0.5766,275 shs84,467 shsULURULURU$0.00$0.10▼$0.79$5.35M-3.136,691 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma+2.64%-0.85%-1.69%+20.73%-4.12%FNCHFinch Therapeutics Group-0.24%-2.54%+1.81%-7.52%+1.04%NEUPNeuphoria Therapeutics+16.24%+26.36%+103.23%+111.19%+1,509,999,900.00%ULURULURU0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 3.00Buy$10.00329.18% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/ANEUPNeuphoria Therapeutics 3.00Buy$21.0039.07% UpsideULURULURU 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ULUR, NEUP, AYTU, and FNCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025NEUPNeuphoria TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.007/1/2025AYTUAytu BioPharmaLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.006/30/2025AYTUAytu BioPharmaAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$81M0.26N/AN/A$4.64 per share0.50FNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/ANEUPNeuphoria Therapeutics$10K2,838.80N/AN/A$15.85 per share0.95ULURULURUN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%9/25/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/ANEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)ULURULURUN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest ULUR, NEUP, AYTU, and FNCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/29/2025N/ANEUPNeuphoria Therapeutics-$1.26N/AN/AN/AN/AN/A9/25/2025Q4 2025AYTUAytu BioPharma-$0.02N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/AULURULURUN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.271.030.87FNCHFinch Therapeutics GroupN/A3.873.87NEUPNeuphoria TherapeuticsN/A11.0111.01ULURULURUN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%FNCHFinch Therapeutics Group21.77%NEUPNeuphoria Therapeutics15.90%ULURULURUN/AInsider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma3.60%FNCHFinch Therapeutics Group44.90%NEUPNeuphoria Therapeutics0.69%ULURULURU1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataNEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/AULURULURU230.57 million30.24 millionNot OptionableULUR, NEUP, AYTU, and FNCH HeadlinesRecent News About These CompaniesUluru, Fuji and the Great Wall: The most amazing sights to look out for mid-flightSeptember 6, 2025 | telegraph.co.ukVANLIFE in the Red Centre, Part 2 - Outback Australia | Uluru, Kata Tjuta and Kings Canyon | Ep. 14September 6, 2025 | msn.comInfluencers Spark Outrage Over Uluru Photo ControversySeptember 3, 2025 | msn.comSix influencers went on a trip to Uluru and totally missed the pointSeptember 1, 2025 | metro.co.ukM‘Deeply educational’: Influencers defend Uluru trip after backlash over ‘insensitivity’August 31, 2025 | dailytelegraph.com.auDUluru Dialogue pushing to ‘reignite’ Indigenous constitutional recognitionAugust 31, 2025 | skynews.com.auSUluru Dialogue vow to renew recognition fightAugust 29, 2025 | theaustralian.com.auYouTubers Find Out Uluru's Rules Are No JokeAugust 27, 2025 | msn.comOnboard Qantas’ Brand New A220 Over the Australian OutbackAugust 26, 2025 | msn.com‘Not an attractive destination’: Couple films Uluru, commits ’20 fineable offences’August 26, 2025 | msn.comTourists shocked when ordered to delete photos of oft-visited area — and they could have faced a hefty fine: ‘We weren’t aware about that’August 25, 2025 | msn.com‘20 fineable offences’: Aussie couple’s shock email three months after Uluru tripAugust 25, 2025 | news.com.auNTravel vloggers given ’20 fines’ after filming during visit to historic world site – how you can avoid the same mistakeAugust 25, 2025 | thesun.co.ukUluru tourists ordered to delete photos of sacred sites - and they could have faced a hefty fine: ‘We weren’t aware about that’August 25, 2025 | skynews.com.auSVirgin Australia & Starlight Foundation Celebrate 15 Years Of Partnership In The Heart Of AustraliaAugust 21, 2025 | bandt.com.auBStarlight Children’s Foundation and Virgin Australia mark 15 years of granting wishesAugust 20, 2025 | travelweekly.com.auTStarlight Foundation grants ‘unique Uluru experience’ to bring joy ...August 20, 2025 | themercury.com.auTStarlight Foundation grants ‘unique Uluru experience’ to bring joy lil battler following tough diagnosisAugust 18, 2025 | ntnews.com.auNDouglas Crabbe, sentenced to life for Uluru mass murder, has latest parole bid rejectedAugust 16, 2025 | ntnews.com.auNUluru truck mass murderer Douglas Crabbe's parole bid rejected in WAAugust 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Healthcare Pathbreakers With Long-Term TailwindsBy Nathan Reiff | September 1, 2025ULUR, NEUP, AYTU, and FNCH Company DescriptionsAytu BioPharma NASDAQ:AYTU$2.33 +0.06 (+2.64%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$2.31 -0.02 (-1.07%) As of 08:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Finch Therapeutics Group NASDAQ:FNCH$12.67 -0.03 (-0.24%) As of 09/9/2025 01:17 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Neuphoria Therapeutics NASDAQ:NEUP$15.10 +2.11 (+16.24%) As of 09/9/2025 03:59 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.ULURU OTCMKTS:ULURULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
